Researcher
Gregor Verhoef
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Oct 2013 → Today
Projects
1 - 5 of 5
- Genetic drivers of peripheral T-cell lymphomagenesisFrom1 Sep 2017 → 23 Nov 2022Funding: Foundations, funds and other with scientific goal
- The molecular landscape of rare aggressive lymphomasFrom1 Aug 2017 → 1 Dec 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Post-transplant lymphoproliferative disorders: a single center experience over 20 years.From1 Jan 2011 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Physical activity and physical fitness in lymphoma patients before, during and after treatment - a prospective observational study.From1 Oct 2010 → 1 Jun 2013Funding: FWO fellowships
- Whole-body diffusion-weighted MRI in malignant lymphoma: staging and early treatment response assessmentFrom1 Oct 2010 → 8 Jan 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
21 - 30 of 188
- A monocentric retrospective study of 138 therapy-related myeloid neoplasms(2018)
Authors: Helena Claerhout, Lucienne Michaux, Gregor Verhoef, Nancy Boeckx
Pages: 2319 - 2324 - Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly(2018)
Authors: Anika Betsch, Sabien Fevery, Ben Sprangers, Gregor Verhoef, Daan Dierickx, Mariëlle Beckers
Pages: 490 - 498 - Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: A retrospective analysis based on the prospective, international, multicenter PTLD-1 trials.(2018)
Authors: Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, Olivier Gheysens
Pages: 1914 - 1923 - Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study(2018)
Authors: Gregor Verhoef
Pages: 1449 - 1458 - Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study(2018)
Authors: Gregor Verhoef
Pages: 359 - 359 - Role of Interim and End of treatment PET/CT for Response Assessment and Prediction of Relapse in Post-transplant Lymphoproliferative Disorder(2018)
Authors: Vibeke Vergote, Gregor Verhoef, Thomas Tousseyn, Daan Dierickx
Pages: S440 - S441 - Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI(2018)
Authors: Katja De Paepe, Frederik De Keyzer, Oliver Bechter, Daan Dierickx, Ann Janssens, Gregor Verhoef, Raymond Oyen, Vincent Vandecaveye
Pages: 897 - 906 - Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases(2018)
Authors: Lukas Marcelis, Charlien Berghen, Alexandra De Zutter, Peter Vandenberghe, Gregor Verhoef, Olivier Gheysens, Xavier Sagaert, Daan Dierickx, Thomas Tousseyn
Pages: 1457 - 1469 - A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy(2018)
Authors: Gregor Verhoef
Pages: 1351 - 1358 - Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients (vol 9, pg 113, 2016)(2018)
Authors: Julie Morscio, Emilie Bittoun, Nathalie Volders, Eveline Lurquin, Iwona Krajewska, Olivier Gheysens, Peter Vandenberghe, Gregor Verhoef, Philippe Demaerel, Daan Dierickx, et al.
Pages: 65 - 65